In addition, loss of Rb function or genetic ablation of RB1 has been implicated in advanced stages of brain cancers [13, 58], lung cancer [59] and in 25–50% of late stage prostate cancer cases [15, 18]. Here, RB1 is linked to prostate carcinoma.